Automate Your Wheel Strategy on CVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVS
- Rev/Share 305.4036
- Book/Share 61.2567
- PB 1.1587
- Debt/Equity 1.0691
- CurrentRatio 0.8034
- ROIC 0.0353
- MktCap 89823130600.0
- FreeCF/Share 3.7757
- PFCF 18.7914
- PE 19.7877
- Debt/Assets 0.3202
- DivYield 0.0376
- ROE 0.0595
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CVS | UBS | Neutral | Buy | -- | $79 | Aug. 18, 2025 |
| Upgrade | CVS | Robert W. Baird | Neutral | Outperform | -- | $82 | Aug. 14, 2025 |
| Upgrade | CVS | Leerink Partners | Market Perform | Outperform | $55 | $75 | Feb. 13, 2025 |
| Upgrade | CVS | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Feb. 12, 2025 |
| Upgrade | CVS | Edward Jones | Hold | Buy | -- | -- | Jan. 30, 2025 |
| Upgrade | CVS | Deutsche Bank | Hold | Buy | -- | $66 | Dec. 3, 2024 |
| Upgrade | CVS | Barclays | Equal Weight | Overweight | $63 | $82 | Oct. 10, 2024 |
| Upgrade | CVS | TD Cowen | Hold | Buy | $59 | $85 | Oct. 4, 2024 |
News
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
ATTENTION CVS SHAREHOLDERS: Investors Who Lost Money on CVS Health Corporation Are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.
Read More
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
Published: May 07, 2025 by: Yahoo Finance
Sentiment: Positive
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against CVS Health Corporation (“CVS” or the “Company”) (NYSE:CVS). The investigation concerns whether CVS and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Read More
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
Read More
What Makes CVS Health (CVS) a New Buy Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Published: May 01, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
Read More
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
Read More
CVS earnings: Things are finally clicking for the healthcare giant
Published: May 01, 2025 by: Yahoo Finance
Sentiment: Positive
CVS (CVS) stock jumped after beating first quarter earnings and revenue expectations. Jefferies Healthcare Services equity research analyst Brian Tanquilut explains how CVS's margin recovery and business diversification signal growing investor confidence.
Read More
Initial Claims More Than Expectations
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Initial Claims More Than Expectations.
Read More
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation's Q1 2025 earnings show strong growth, with revenues up 7% YoY and adjusted EPS up 72%, but caution is advised for the long-term outlook. Despite positive quarterly results, CVS downgraded its full-year 2025 revenue guidance and faces ongoing challenges in its Medicare Advantage business. CVS is addressing issues in its Health Care Benefits division by terminating unprofitable contracts and improving star ratings, but risks remain high.
Read More
CVS Health (CVS) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation (NYSE:CVS ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President, CVS Health Steve Nelson - President, Aetna Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JP Morgan Stephen Baxter - Wells Fargo Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays Michael Cherny - Leerink Partners Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Operator Good morning and …
Read More
CVS Health raises full-year profit outlook as Q1 earnings top estimates
Published: May 01, 2025 by: Proactive Investors
Sentiment: Positive
CVS Health Corp (NYSE:CVS) shares rose after the pharmacy chain raised its full-year profit guidance and delivered strong financial results for the first quarter. The company now expects 2025 adjusted earnings per share (EPS) in the range of $6 to $6.20, up from its earlier guidance of $5.75 to $6.
Read More
Compared to Estimates, CVS Health (CVS) Q1 Earnings: A Look at Key Metrics
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
QCOM Earnings Sell-Off, CVS Turnaround Continues, LLY Disappoints
Published: May 01, 2025 by: Schwab Network
Sentiment: Neutral
While Microsoft (MSFT) and Meta Platforms (META) shined in the Big Tech space, Diane King Hall turns to a mixed earnings picture elsewhere on Wall Street. CVS Health (CVS) posted an earnings beat, raised guidance, and announced a Wegovy deal with Novo Nordisk (NVO), all contributing to its rally.
Read More
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Read More
CVS Health Stock Surges as Q1 Results Handily Top Estimates
Published: May 01, 2025 by: Investopedia
Sentiment: Positive
CVS Health (CVS) shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results handily topped estimates.
Read More
CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago.
Read More
CVS Health's stock surges toward a one-year high after an earnings triple play
Published: May 01, 2025 by: Market Watch
Sentiment: Positive
Shares of CVS Health Corp. CVS jumped 6.6% toward a one-year high in premarket trading Thursday, after the healthcare-services company and drugstore chain scored a triple-play with its earnings report, by beating and profit and revenue and raising its full-year outlook.
Read More
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
Read More
CVS tops estimates, hikes guidance as insurance business shows some improvement
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health reported first-quarter revenue and profit that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period. The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per share.
Read More
CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior year GAAP diluted EPS of $1.41 and Adjusted EPS of $2.25 Generated cash flow from operations of $4.6 billion Operational Highlights CVS Health to exit the individual exchange business Aetna® introduces new solutions to ease the patient and provider experience CVS Caremark® makes formulary update to improve access to GLP-1 drugs 2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83 Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00 Raised cash flow from …
Read More
CVS Beats Wall Street Expectations, Plans to Withdraw From ACA Business
Published: May 01, 2025 by: WSJ
Sentiment: Positive
The healthcare company also struck a deal with Novo Nordisk to sell Wegovy at a reduced price for cash-paying customers through its pharmacies.
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
CVS Health: Maybe The Right Investment At The Right Time
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
CVS Health Corporation surged 10% intraday and ended yesterday 6% higher, driven by a new CFO announcement and increased Medicare Advantage payments. Despite a challenging fiscal 2024, CVS is undervalued with strong growth potential, expecting 3.5% revenue growth and 6-11% EPS growth in 2025. CVS remains a solid investment due to its recession-resilient business model, low tariff impact, and trading below intrinsic value.
Read More
CVS Health (CVS) Surges 5.9%: Is This an Indication of Further Gains?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
About CVS Health Corporation (CVS)
- IPO Date 1996-11-20
- Website https://www.cvshealth.com
- Industry Medical - Healthcare Plans
- CEO J. David Joyner CEBS
- Employees 219000